romiplostim

Known as: Amgen Megakaryopoiesis Protein 2 
A drug used to treat patients with immune thrombocytopenic purpura (ITP) who do not get better with other forms of treatment. In ITP, platelets… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Romiplostim was effective, safe, and well-tolerated over 6-12 months of continuous treatment in Phase 3 trials in patients with… (More)
Is this relevant?
Review
2013
Review
2013
RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts in adults with immune thrombocytopenia… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts and mucocutaneous bleeding. In previous… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Romiplostim is a thrombopoietin receptor agonist that increases platelet counts in patients with chronic immune thrombocytopenia… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2009
Review
2009
Thrombopoietin (TPO) is the physiologic regulator of platelet production and works by binding to its receptor on megakaryocyte… (More)
Is this relevant?
2001
2001
Contrasting with improved survival for most other gastrointestinal cancers, the 5-year survival of patients with ductal… (More)
  • table 1
  • figure 1
  • table 3
  • table 2
  • table 4
Is this relevant?